NO996270L - Treatment of diabetes with thiazolidinedione and <alfa> glucosidase inhibitor - Google Patents

Treatment of diabetes with thiazolidinedione and <alfa> glucosidase inhibitor

Info

Publication number
NO996270L
NO996270L NO996270A NO996270A NO996270L NO 996270 L NO996270 L NO 996270L NO 996270 A NO996270 A NO 996270A NO 996270 A NO996270 A NO 996270A NO 996270 L NO996270 L NO 996270L
Authority
NO
Norway
Prior art keywords
glucosidase inhibitor
thiazolidinedione
alfa
diabetes
treatment
Prior art date
Application number
NO996270A
Other languages
Norwegian (no)
Other versions
NO996270D0 (en
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712865.6A external-priority patent/GB9712865D0/en
Priority claimed from GBGB9806708.5A external-priority patent/GB9806708D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO996270D0 publication Critical patent/NO996270D0/en
Publication of NO996270L publication Critical patent/NO996270L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Fodder In General (AREA)

Abstract

En fremgangsmåte for behandlingen av diabetes mellitus og tilstander som er assosiert med diabetes mellitus i et pattedyr, der fremgangsmåten innbefatter administrering av en effektiv ikke-toksisk og farmasøytiske godkjent mengde av en insulinsensitiverer og en antihyperglykemisk alfa-glukosidaseinhibitoragens til et pattedyr med behov derav.A method of treating diabetes mellitus and conditions associated with diabetes mellitus in a mammal, the method comprising administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitizer and an antihyperglycemic alpha-glucosidase inhibitor agent to a mammal.

NO996270A 1997-06-18 1999-12-17 Treatment of diabetes with thiazolidinedione and <alfa> glucosidase inhibitor NO996270L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9712865.6A GB9712865D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806708.5A GB9806708D0 (en) 1998-03-27 1998-03-27 Novel method
PCT/EP1998/003691 WO1998057635A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor

Publications (2)

Publication Number Publication Date
NO996270D0 NO996270D0 (en) 1999-12-17
NO996270L true NO996270L (en) 1999-12-17

Family

ID=26311746

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996270A NO996270L (en) 1997-06-18 1999-12-17 Treatment of diabetes with thiazolidinedione and <alfa> glucosidase inhibitor

Country Status (24)

Country Link
EP (1) EP0975343A1 (en)
JP (1) JP2001523271A (en)
KR (1) KR20010013845A (en)
CN (1) CN1274282A (en)
AP (1) AP9901720A0 (en)
AR (2) AR013352A1 (en)
AU (1) AU8799998A (en)
BG (1) BG103966A (en)
BR (1) BR9810186A (en)
CA (1) CA2294134A1 (en)
CO (1) CO4940453A1 (en)
DZ (1) DZ2519A1 (en)
EA (1) EA200000040A1 (en)
IL (1) IL133138A0 (en)
MA (1) MA26510A1 (en)
NO (1) NO996270L (en)
NZ (1) NZ501345A (en)
OA (1) OA11631A (en)
PE (1) PE89199A1 (en)
PL (1) PL337577A1 (en)
SK (1) SK179499A3 (en)
TR (1) TR199903072T2 (en)
UY (1) UY25051A1 (en)
WO (1) WO1998057635A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200103061T2 (en) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. New pharmaceutical ingredient.
WO2002080936A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
JP4590158B2 (en) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Combination therapy comprising a glucose reabsorption inhibitor and a retinoid-X receptor modulator
FR2832930A1 (en) * 2001-12-03 2003-06-06 Lipha PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR THE PREPARATION OF MEDICINES FOR TREATING DIABETES
JP2004067575A (en) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd Promoter for effect of therapeutic agent for diabetes
CN101121004B (en) * 2006-08-08 2010-07-21 鲁南制药集团股份有限公司 Medicine composition containing insulin intensifier and miglitol
CN101584705B (en) * 2008-05-24 2010-10-27 鲁南制药集团股份有限公司 Medicament composition for treating diabetes and complications of diabetes
CN101584688B (en) * 2008-05-24 2010-11-10 鲁南制药集团股份有限公司 Medicament composition for treating diabetes and complications of diabetes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
AU8799998A (en) 1999-01-04
WO1998057635A1 (en) 1998-12-23
AR014881A1 (en) 2001-04-11
JP2001523271A (en) 2001-11-20
IL133138A0 (en) 2001-03-19
BR9810186A (en) 2000-08-08
UY25051A1 (en) 2000-09-29
EP0975343A1 (en) 2000-02-02
CN1274282A (en) 2000-11-22
MA26510A1 (en) 2004-12-20
PE89199A1 (en) 1999-10-23
NO996270D0 (en) 1999-12-17
CA2294134A1 (en) 1998-12-23
AR013352A1 (en) 2000-12-27
OA11631A (en) 2004-11-22
BG103966A (en) 2000-07-31
KR20010013845A (en) 2001-02-26
TR199903072T2 (en) 2000-07-21
NZ501345A (en) 2001-10-26
PL337577A1 (en) 2000-08-28
CO4940453A1 (en) 2000-07-24
AP9901720A0 (en) 1999-12-31
SK179499A3 (en) 2000-11-07
DZ2519A1 (en) 2003-02-01
EA200000040A1 (en) 2000-08-28

Similar Documents

Publication Publication Date Title
NO20090846L (en) Combination and pharmaceutical composition for the treatment of diabetes and its use
MXPA02012763A (en) Combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabete mellitus.
CY1105254T1 (en) TREATMENT OF DIABETES WITH A THIAZOLIDINEDIONE, AN INSULIN SECRETAGO AND DIGUANIDIUM
UY25713A1 (en) METHOD FOR TREATING DIABETES USING AN AP2 INHIBITOR AND COMBINATION.
NO20083276L (en) Treatment of diabetes with thiazolidinedione and sulfonylurea
NO996270L (en) Treatment of diabetes with thiazolidinedione and &lt;alfa&gt; glucosidase inhibitor
NO20000230L (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and &lt;alfa&gt; glucosidase inhibitor
BR9810444A (en) Treatment of diabetes with rosiglitazone and insulin
MY138246A (en) Treatment of diabetes with thiazolidione and sulphonylurea.
TR200101336T2 (en) Combinations with a beta-agonist and another antidiabetic agent
WO2001047509A3 (en) Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
ECSP982592A (en) NEW METHOD OF TREATMENT V
CO5150158A1 (en) NEW ANTIDIABETIC TREATMENT
TR200000957T2 (en) The use of thiazolidinedione in the treatment of hyperglycemia
HUP0002569A2 (en) Pharmaceutical compositions for treatment of diabetes containing thiazolidinedione and alpha-glucosidase inhibitors
ECSP982591A (en) NEW METHOD OF TREATMENT IV
ECSP982542A (en) NEW METHOD OF TREATMENT III
TR200000958T2 (en) The use of thiazolidinedione in the treatment of hyperglycemia.
ECSP982593A (en) NEW METHOD OF TREATMENT VI
ECSP982535A (en) NEW TREATMENT METHOD (I)
ECSP993146A (en) TREATMENT METHOD FOR DIABETES USING AN AP2 INHIBITOR AND ITS COMBINATION
HUP0002668A2 (en) Treatment of diabetes with thiazolidinedione and metformin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application